XENE vs. SUPN, SAGE, VYGR, MRNS, SRPT, CTLT, ROIV, ELAN, INSM, and ASND
Should you be buying Xenon Pharmaceuticals stock or one of its competitors? The main competitors of Xenon Pharmaceuticals include Supernus Pharmaceuticals (SUPN), Sage Therapeutics (SAGE), Voyager Therapeutics (VYGR), Marinus Pharmaceuticals (MRNS), Sarepta Therapeutics (SRPT), Catalent (CTLT), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Insmed (INSM), and Ascendis Pharma A/S (ASND). These companies are all part of the "medical" sector.
Xenon Pharmaceuticals (NASDAQ:XENE) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership, earnings and community ranking.
Supernus Pharmaceuticals has higher revenue and earnings than Xenon Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Xenon Pharmaceuticals had 6 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 10 mentions for Xenon Pharmaceuticals and 4 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.33 beat Xenon Pharmaceuticals' score of 0.94 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.
Xenon Pharmaceuticals presently has a consensus target price of $59.11, suggesting a potential upside of 55.27%. Supernus Pharmaceuticals has a consensus target price of $41.00, suggesting a potential upside of 51.18%. Given Xenon Pharmaceuticals' higher probable upside, equities analysts clearly believe Xenon Pharmaceuticals is more favorable than Supernus Pharmaceuticals.
Xenon Pharmaceuticals has a net margin of 0.00% compared to Supernus Pharmaceuticals' net margin of -2.60%. Supernus Pharmaceuticals' return on equity of -1.68% beat Xenon Pharmaceuticals' return on equity.
Supernus Pharmaceuticals received 63 more outperform votes than Xenon Pharmaceuticals when rated by MarketBeat users. Likewise, 73.25% of users gave Supernus Pharmaceuticals an outperform vote while only 69.39% of users gave Xenon Pharmaceuticals an outperform vote.
Xenon Pharmaceuticals has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.
95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 5.5% of Xenon Pharmaceuticals shares are owned by company insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Supernus Pharmaceuticals beats Xenon Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Xenon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XENE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xenon Pharmaceuticals Competitors List
Related Companies and Tools
